查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046999

冠狀動脈聚合物內支架市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、地區和競爭對手分類，2021-2031年

Coronary Artery Polymer Endostents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球冠狀動脈聚合物內支架市場預計將從 2025 年的 47.5 億美元成長到 2031 年的 66.5 億美元，複合年成長率為 5.77%。

這些先進的介入器械，包括聚合物塗層藥物釋放型支架和生物可吸收支架，對於維持血管通暢性和輸送抗增殖藥物以治療冠狀動脈疾病至關重要。市場成長的主要促進因素是全球心血管疾病發生率的上升和人口老化，這兩方面都要求有效且微創的經皮冠狀動脈介入治療。美國心臟協會2025年報告強調了持續創新生物相容性聚合物技術以改善癒合和臨床療效的迫切需求。報告指出，心血管疾病仍是全球首要死因，每年造成約1,941萬人死亡。

市場概覽
預測期 2027-2031
市場規模：2025年 47.5億美元
市場規模：2031年 66.5億美元
複合年成長率：2026-2031年 5.77%
成長最快的細分市場 急性心肌梗塞
最大的市場 北美洲

儘管市場需求強勁，但由於III類醫療設備監管環境嚴格，市場仍面臨許多障礙。製造商必須遵守複雜的核准流程，檢驗聚合物分解的安全性，並提交詳盡的長期臨床數據以降低諸如支架血栓症延遲形成等風險。這種嚴格的監管可能會顯著延遲產品上市，並阻礙整體市場成長。

市場促進因素

全球冠狀動脈疾病盛行率的不斷上升是推動冠狀動脈聚合物內支架應用日益廣泛的主要動力。隨著心血管疾病的日益普遍，尤其是在老齡化社會中，需要先進支架解決方案的經皮冠狀動脈介入治療（PCI）的數量也在增加。這種不斷成長的需求體現在強勁的業績表現上，例如波士頓科學公司心血管事業部報告稱，其2024年第四季度和全年淨銷售額成長了28.8%，凸顯了對有效介入治療的迫切需求。此外，這種需求正在全球範圍內不斷擴大，Terumo Corporation介入系統事業部在截至2025年3月31日的會計年度中，海外市場銷售額成長了15.2%，這主要得益於全球介入治療基礎設施的完善。

生物可吸收聚合物材料的重大技術進步也是推動這一領域發展的主要動力，它克服了永久性金屬植入的固有限制。創新日益集中於開發可在逐漸分解前提供臨時血管支撐的聚合物支架，從而恢復血管的自然運動性並減輕諸如支架延遲血栓症等長期併發症。這一臨床轉變得到了令人信服的長期療效數據的支持。例如，在2025年歐洲經皮冠狀動脈介入治療大會（EuroPCR 2025）上，Elixir Medical公司宣布，其DynamX Bioadaptor系統的3年目標病變失敗率（TLF）顯著降低至2.7%，而標準藥物釋放型支架的TLF為7.2%。聚合物科學的這些進步不僅將提高病患安全性，還將加速下一代支架的監管核准和商業化進程。

市場挑戰

針對III類醫療設備的嚴格法規結構嚴重阻礙了全球冠狀動脈聚合物支架市場的成長。製造商必須經歷複雜的上市前核准流程，該流程要求提供大量的長期臨床數據，以檢驗聚合物分解的安全性以及預防再血管再阻塞的有效性。這種嚴格的審查流程顯著增加了研發成本，並成為產品商業化過程中的一個主要瓶頸，尤其對於那些可能缺乏長期臨床試驗所需資源的小規模創新公司而言更是如此。

因此，這些監管壁壘直接阻礙了先進支架技術的市場准入。根據歐洲醫療技術協會（MedTech Europe）預測，到2025年，在現行法規結構下，醫療設備的平均認證時間將延長至13至18個月，相當於先前所需時間的兩倍。如此漫長的核准流程不僅延緩了製造商的產生收入，也限制了新一代聚合物內支架的供應，最終減緩了全球市場的整體擴張和活力。

市場趨勢

製造商正致力於設計具有超薄支架梁（通常小於60微米）的聚合物塗層支架，以滿足臨床對更佳貼合度和減少血管損傷的需求。這種設計改進旨在最大限度地減少血流干擾並促進內皮化，最終降低冠狀動脈解剖結構複雜患者的血管再阻塞率。領先的研發公司優先考慮這些創新，其強勁的業績顯示市場對這些先進特性的認可度很高。例如，波士頓科學公司心血管部門報告稱，2025年第三季淨銷售額成長了22.4%，證實了這些高性能介入技術的加速應用。這一趨勢表明，在保持徑向支撐強度和輸送性能的同時，器械的外形尺寸將繼續縮小。

在亞太和拉丁美洲等新興地區，生產在地化進程的快速推進以及經濟高效的生物分解聚合物支架的廣泛應用是顯著的市場趨勢。這種策略擴張正在積極重塑競爭格局，因為本土企業正利用以價值為導向的採購模式，採用先前由全球巨頭主導的先進技術。這種朝向更經濟實惠的在地化解決方案的轉變，正在推動價格敏感型市場銷售的顯著成長。微創醫療2024會計年度業績顯示，其國際收入年增85%，顯示以價值為導向的競爭對手已成功滲透全球市場，並從根本上改變了全球冠心病治療的價格趨勢和可及性。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球冠狀動脈聚合物支架市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（PLGA、PLLA、PDLA、脫氨酪胺聚碳酸酯、Yukatec）
    • 依應用領域（急性心肌梗塞、急性血管阻塞等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美冠狀動脈聚合物支架市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲冠狀動脈聚合物支架市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區冠狀動脈聚合物支架市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲冠狀動脈聚合物支架市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲冠狀動脈聚合物支架市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球冠狀動脈聚合物支架市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott Laboratories
  • Medtronic plc
  • Boston Scientific Corporation
  • Biotronik SE & Co. KG
  • Elixir Medical Corporation
  • REVA Medical, LLC
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • Arterial Remodeling Technologies SA
  • Eucatech AG

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16731

The Global Coronary Artery Polymer Endostents Market is projected to expand from USD 4.75 Billion in 2025 to USD 6.65 Billion by 2031, demonstrating a 5.77% CAGR. These advanced interventional devices, which include polymer-coated drug-eluting stents and bioresorbable scaffolds, are crucial for maintaining vessel patency and delivering anti-proliferative medications to treat coronary artery disease. The market's growth is primarily fueled by the increasing worldwide incidence of cardiovascular conditions and an aging population, both of which necessitate effective, minimally invasive percutaneous coronary interventions. The critical need for continuous innovation in biocompatible polymer technologies that enhance healing and clinical outcomes is highlighted by the American Heart Association's 2025 report, which stated cardiovascular disease remained the leading global cause of mortality, responsible for approximately 19.41 million deaths annually.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.75 Billion
Market Size 2031USD 6.65 Billion
CAGR 2026-20315.77%
Fastest Growing SegmentAcute Myocardial Infarction
Largest MarketNorth America

Despite this robust demand, the market faces a significant hurdle due to the stringent regulatory landscape governing Class III medical devices. Manufacturers must successfully navigate intricate approval processes and supply extensive long-term clinical data to verify the safety of polymer degradation and mitigate risks such as late stent thrombosis. This rigorous oversight can substantially delay product commercialization and impede overall market expansion.

Market Driver

The escalating global prevalence of coronary artery disease serves as the primary impetus for the increased adoption of coronary artery polymer endostents. As cardiovascular conditions become more widespread, particularly within the aging demographic, there is a corresponding rise in the volume of percutaneous coronary interventions that require advanced scaffolding solutions. This heightened demand is reflected in strong financial performances, such as Boston Scientific's Cardiovascular segment reporting 28.8% net sales growth in Q4 and Full Year 2024, emphasizing the urgent need for effective interventional therapies. Furthermore, this demand is expanding globally, with Terumo Corporation's Interventional Systems division experiencing a 15.2% revenue increase in overseas markets for the fiscal year ended March 31, 2025, driven by the worldwide growth of interventional infrastructure.

Significant technological advancements in bioresorbable polymer materials are also a key driver, addressing the inherent limitations of permanent metallic implants. Innovation is increasingly centered on developing polymer scaffolds that provide temporary vessel support before gradually degrading, thereby restoring natural vascular vasomotion and reducing long-term complications like late stent thrombosis. This clinical shift is bolstered by compelling long-term efficacy data; for instance, Elixir Medical announced at EuroPCR 2025 that its DynamX Bioadaptor system demonstrated a significantly lower Target Lesion Failure rate of 2.7% at three years compared to 7.2% for a standard drug-eluting stent. Such progress in polymer science not only improves patient safety but also expedites the regulatory approval and commercialization of next-generation scaffolds.

Market Challenge

The rigorous regulatory framework governing Class III medical devices significantly hinders the growth of the Global Coronary Artery Polymer Endostents Market. Manufacturers are obligated to navigate complex pre-market approval processes that mandate extensive long-term clinical data to validate both the safety of polymer degradation and the efficacy in preventing restenosis. This stringent scrutiny substantially increases development costs and creates considerable bottlenecks in the product commercialization pipeline, especially for smaller innovators who may lack the resources required for prolonged clinical trials.

Consequently, these regulatory obstacles directly delay the market entry of advanced stent technologies. According to MedTech Europe, in 2025, the average time-to-certification for medical devices under the current regulatory framework expanded to between 13 and 18 months, effectively doubling the duration of previous requirements. Such extended approval timelines not only postpone revenue generation for manufacturers but also restrict the availability of next-generation polymer endostents to healthcare providers, thereby dampening the overall expansion and dynamism of the global market.

Market Trends

Manufacturers are increasingly concentrating on designing polymer-coated stents with ultrathin struts, typically less than 60 microns, to meet clinical demands for enhanced conformability and reduced vessel injury. This design evolution aims to minimize flow disturbances and accelerate endothelialization, ultimately leading to lower restenosis rates in patients with complex coronary anatomies. The market's embrace of such advanced capabilities is evident in the strong performance of leading developers who prioritize these engineering innovations; for example, Boston Scientific's Cardiovascular segment reported 22.4% net sales growth in Q3 2025, confirming the accelerated adoption of these high-performance interventional technologies. This trend signifies a lasting shift towards lower-profile devices that maintain both radial strength and deliverability.

In emerging regions such as Asia-Pacific and Latin America, a prominent market trend is the rapid localization of manufacturing and the introduction of cost-effective biodegradable polymer stents. This strategic expansion is actively reshaping the competitive landscape as local players leverage value-based procurement models to introduce advanced technologies previously dominated by global heavyweights. This shift towards more affordable, locally produced solutions is driving substantial volume growth in price-sensitive markets. MicroPort Scientific Corporation's 2024 annual results, which reported an 85% year-on-year increase in its overseas business revenue, underscore the successful penetration of these value-driven competitors into the global arena, fundamentally altering the pricing dynamics and accessibility of coronary therapies worldwide.

Key Market Players

  • Abbott Laboratories
  • Medtronic plc
  • Boston Scientific Corporation
  • Biotronik SE & Co. KG
  • Elixir Medical Corporation
  • REVA Medical, LLC
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • Arterial Remodeling Technologies SA
  • Eucatech AG

Report Scope

In this report, the Global Coronary Artery Polymer Endostents Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Coronary Artery Polymer Endostents Market, By Type

  • PLGA
  • PLLA
  • PDLA
  • Deamination Tyramine Polycarbonateeucatech

Coronary Artery Polymer Endostents Market, By Application

  • Acute Myocardial Infarction
  • Acute Vascular Blockage
  • Other

Coronary Artery Polymer Endostents Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Coronary Artery Polymer Endostents Market.

Available Customizations:

Global Coronary Artery Polymer Endostents Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Coronary Artery Polymer Endostents Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (PLGA, PLLA, PDLA, Deamination Tyramine Polycarbonateeucatech)
    • 5.2.2. By Application (Acute Myocardial Infarction, Acute Vascular Blockage, Other)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Coronary Artery Polymer Endostents Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Coronary Artery Polymer Endostents Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Coronary Artery Polymer Endostents Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Coronary Artery Polymer Endostents Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application

7. Europe Coronary Artery Polymer Endostents Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Coronary Artery Polymer Endostents Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
    • 7.3.2. France Coronary Artery Polymer Endostents Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Coronary Artery Polymer Endostents Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Coronary Artery Polymer Endostents Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Coronary Artery Polymer Endostents Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application

8. Asia Pacific Coronary Artery Polymer Endostents Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Coronary Artery Polymer Endostents Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
    • 8.3.2. India Coronary Artery Polymer Endostents Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Coronary Artery Polymer Endostents Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Coronary Artery Polymer Endostents Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Coronary Artery Polymer Endostents Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application

9. Middle East & Africa Coronary Artery Polymer Endostents Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Coronary Artery Polymer Endostents Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Coronary Artery Polymer Endostents Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Coronary Artery Polymer Endostents Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application

10. South America Coronary Artery Polymer Endostents Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Coronary Artery Polymer Endostents Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Coronary Artery Polymer Endostents Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Coronary Artery Polymer Endostents Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Coronary Artery Polymer Endostents Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Medtronic plc
  • 15.3. Boston Scientific Corporation
  • 15.4. Biotronik SE & Co. KG
  • 15.5. Elixir Medical Corporation
  • 15.6. REVA Medical, LLC
  • 15.7. Meril Life Sciences Pvt. Ltd.
  • 15.8. MicroPort Scientific Corporation
  • 15.9. Arterial Remodeling Technologies SA
  • 15.10. Eucatech AG

16. Strategic Recommendations

17. About Us & Disclaimer